Biomm

Biomm CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Biomm (BIOM3.SA) as of Nov 11, 2026 is -23.76 %. In the previous year, CapEx to Operating Cash Flow Ratio was -20.86 % — a change of 13.89% (lower).

CapEx/OCF

-23.76 %

YoY

13.89%

Last updated:

CapEx to Operating Cash Flow Ratio of Biomm is 2025 -23.76 % . CapEx to Operating Cash Flow Ratio of Biomm was 2024 -20.86 % . It decreases by 13.89% lower compared to the previous year.

The Biomm CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-2.06 BRL
Jan 1, 2019
-9.47 BRL
Jan 1, 2020
-4.78 BRL
Jan 1, 2021
-7.94 BRL
Jan 1, 2022
-8.63 BRL
Jan 1, 2023
-8.32 BRL
Jan 1, 2024
-20.86 BRL
Jan 1, 2025
-23.76 BRL
The Biomm CapEx/OCF history
YEARCapEx/OCFYoY
-23.76 %+13.89%
-20.86 %+150.71%
-8.32 %-3.63%
-8.63 %+8.80%
-7.94 %+66.14%
-4.78 %-49.57%
-9.47 %+359.64%
-2.06 %-80.70%
-10.67 %-93.53%
-164.97 %-33.18%
-246.88 %+107.47%
-119.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

CapEx to Operating Cash Flow Ratio of Biomm is -23.76 % in 2025.

CapEx to Operating Cash Flow Ratio of Biomm changed from -20.86 % to -23.76 %, representing a 13.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Biomm since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Biomm with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biomm

All Key Metrics — Biomm